These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34214631)

  • 1. Targeting HDAC8 to ameliorate skeletal muscle differentiation in Duchenne muscular dystrophy.
    Spreafico M; Cafora M; Bragato C; Capitanio D; Marasca F; Bodega B; De Palma C; Mora M; Gelfi C; Marozzi A; Pistocchi A
    Pharmacol Res; 2021 Aug; 170():105750. PubMed ID: 34214631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy.
    Farr GH; Morris M; Gomez A; Pham T; Kilroy E; Parker EU; Said S; Henry C; Maves L
    Skelet Muscle; 2020 Oct; 10(1):29. PubMed ID: 33059738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Givinostat as metabolic enhancer reverting mitochondrial biogenesis deficit in Duchenne Muscular Dystrophy.
    Giovarelli M; Zecchini S; Catarinella G; Moscheni C; Sartori P; Barbieri C; Roux-Biejat P; Napoli A; Vantaggiato C; Cervia D; Perrotta C; Clementi E; Latella L; De Palma C
    Pharmacol Res; 2021 Aug; 170():105751. PubMed ID: 34197911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular Dystrophies.
    Sandonà M; Cavioli G; Renzini A; Cedola A; Gigli G; Coletti D; McKinsey TA; Moresi V; Saccone V
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients.
    Mozzetta C; Sartorelli V; Steinkuhler C; Puri PL
    Trends Mol Med; 2024 Mar; 30(3):278-294. PubMed ID: 38408879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
    Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
    Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pan HDAC inhibitor Givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene.
    Licandro SA; Crippa L; Pomarico R; Perego R; Fossati G; Leoni F; Steinkühler C
    Skelet Muscle; 2021 Jul; 11(1):19. PubMed ID: 34294164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoplasmic HDAC4 regulates the membrane repair mechanism in Duchenne muscular dystrophy.
    Renzini A; Marroncelli N; Cavioli G; Di Francescantonio S; Forcina L; Lambridis A; Di Giorgio E; Valente S; Mai A; Brancolini C; Giampietri C; Magenta A; De Santa F; Adamo S; Coletti D; Moresi V
    J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1339-1359. PubMed ID: 35170869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat.
    Consalvi S; Mozzetta C; Bettica P; Germani M; Fiorentini F; Del Bene F; Rocchetti M; Leoni F; Monzani V; Mascagni P; Puri PL; Saccone V
    Mol Med; 2013 May; 19(1):79-87. PubMed ID: 23552722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6.
    Vanaja GR; Ramulu HG; Kalle AM
    Cell Commun Signal; 2018 May; 16(1):20. PubMed ID: 29716651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histological effects of givinostat in boys with Duchenne muscular dystrophy.
    Bettica P; Petrini S; D'Oria V; D'Amico A; Catteruccia M; Pane M; Sivo S; Magri F; Brajkovic S; Messina S; Vita GL; Gatti B; Moggio M; Puri PL; Rocchetti M; De Nicolao G; Vita G; Comi GP; Bertini E; Mercuri E
    Neuromuscul Disord; 2016 Oct; 26(10):643-649. PubMed ID: 27566866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC8 regulates canonical Wnt pathway to promote differentiation in skeletal muscles.
    Ferrari L; Bragato C; Brioschi L; Spreafico M; Esposito S; Pezzotta A; Pizzetti F; Moreno-Fortuny A; Bellipanni G; Giordano A; Riva P; Frabetti F; Viani P; Cossu G; Mora M; Marozzi A; Pistocchi A
    J Cell Physiol; 2019 May; 234(5):6067-6076. PubMed ID: 30246374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase 8 regulates cortactin deacetylation and contraction in smooth muscle tissues.
    Li J; Chen S; Cleary RA; Wang R; Gannon OJ; Seto E; Tang DD
    Am J Physiol Cell Physiol; 2014 Aug; 307(3):C288-95. PubMed ID: 24920679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
    Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM
    Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment.
    Colussi C; Mozzetta C; Gurtner A; Illi B; Rosati J; Straino S; Ragone G; Pescatori M; Zaccagnini G; Antonini A; Minetti G; Martelli F; Piaggio G; Gallinari P; Steinkuhler C; Clementi E; Dell'Aversana C; Altucci L; Mai A; Capogrossi MC; Puri PL; Gaetano C
    Proc Natl Acad Sci U S A; 2008 Dec; 105(49):19183-7. PubMed ID: 19047631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC8 Inhibition Blocks SMC3 Deacetylation and Delays Cell Cycle Progression without Affecting Cohesin-dependent Transcription in MCF7 Cancer Cells.
    Dasgupta T; Antony J; Braithwaite AW; Horsfield JA
    J Biol Chem; 2016 Jun; 291(24):12761-12770. PubMed ID: 27072133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors: a potential epigenetic treatment for Duchenne muscular dystrophy.
    Consalvi S; Saccone V; Mozzetta C
    Epigenomics; 2014; 6(5):547-60. PubMed ID: 25431946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants.
    Marek M; Shaik TB; Heimburg T; Chakrabarti A; Lancelot J; Ramos-Morales E; Da Veiga C; Kalinin D; Melesina J; Robaa D; Schmidtkunz K; Suzuki T; Holl R; Ennifar E; Pierce RJ; Jung M; Sippl W; Romier C
    J Med Chem; 2018 Nov; 61(22):10000-10016. PubMed ID: 30347148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.